14
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Bone Mineral Density and Biochemical Parameters of Bone Turnover in Children with Growth Hormone Deficiency

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Growth hormone (GH) is a crucial factor in the build-up and in the maintenance of peak bone mass. Children with GH deficiency have osteopenia and a concomitant reduction in bone turnover. On the other hand, GH therapy improves bone mineral density and stimulates bone turnover. These data suggest that GH treatment may have a beneficial effect on peak bone mass. In children with GH deficiency, the values of some biochemical markers of bone turnover may be closely related to growth response during GH therapy. However, further studies are needed to define the usefulness of bone markers in order to optimize the treatment and to predict the growth outcome in GH-treated children.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-6322-2
          978-3-318-01550-8
          1663-2818
          1663-2826
          1996
          1996
          10 December 2008
          : 45
          : Suppl 1
          : 67-68
          Affiliations
          Endocrine Unit, Chair of Preventive Paediatrics, Department of Paediatrics, University of Pisa, Italy
          Article
          184835 Horm Res 1996;45:67–68
          10.1159/000184835
          8805036
          ba5abd85-f95f-4e49-a3f0-e71c1c23ad20
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 2
          Categories
          Symposium III: Bone Biology and Growth

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Osteopenia,Biochemical bone markers,Peak bone mass,Bone turnover,Growth hormone deficiency,Growth hormone therapy,Bone mineral density

          Comments

          Comment on this article